Little-Known Pharma Eyes $1 Billion Blockbuster as Wall Street Analyst Raises Target – Suggesting Significant Upside Potential… (1)(2)

See why now could be the best time to start your research on XORTX Therapeutics Inc. (Nasdaq: XRTX).

BREAKING NEWS

XORTX Reprices Warrants Issued in Connection with Previous Private Placements

Understanding Blockbusters in the Pharmaceutical Industry (3)

Image Source (4)

Blockbuster dr-ugs play a pivotal role in the pharmaceutical industry, representing a pinnacle of success and innovation. (3) 

These medications have the remarkable ability to generate annual sales exceeding $1 billion for the companies that develop and market them.

What Is a Blockbuster? (3)

A blockbuster dr-ug is a pharmaceutical product that achieves an extraordinary level of popularity and financial success by generating annual sales surpassing the billion-dollar mark for the company responsible for its development and distribution.

These medications are often considered game-changers, addressing common medical conditions that affect a substantial portion of the population.

Common Examples of Blockbusters: (3)

Several blockbuster dr-ugs have made significant impacts on the healthcare industry, benefiting countless patients worldwide.

Some well-known examples include Vioxx, Lipitor, and Zoloft.

These medications have been instrumental in managing various health conditions, including high cholesterol, diabetes, high blood pressure, asthma, and cancer.

The Road to Blockbuster Status: (3)

Pharmaceutical companies spend substantial resources in research and development (R&D) to discover and develop novel dr-ugs.

This process can be both time-consuming and expensive, with development timelines spanning several years and costs running into hundreds of millions of dollars.

When a pharmaceutical company successfully creates a dr-ug that demonstrates efficacy and gains approval from regulatory authorities, such as the Food and Dr-ug Administration (FDA), they are granted a patent.

The Importance of Patents: (3)

A patent bestows exclusive rights upon the pharmaceutical company, allowing them to be the sole provider of the dr-ug for a predetermined period, often extending for several years.

During this time, the company can set the dr-ug’s price without competition, aiming to recover the substantial R&D costs and realize a profit.

The Significance of Blockbusters: (3)

A blockbuster dr-ug can be a game-changer for a pharmaceutical company, driving substantial revenue and contributing to its overall success.

These medications have the potential to transform healthcare by offering effective solutions to prevalent medical conditions.

Navigating the Pharmaceutical Landscape:

In the dynamic world of pharmaceuticals, XORTX Therapeutics Inc. (Nasdaq: XRTX) stands as a little-known player with significant potential. (1)

Recently, on 1/3/2024, XORTX Therapeutics Inc. (Nasdaq: XRTX) submitted a new patent application for the treatment of Chronic Kidney Disease (CKD), emphasizing its commitment to addressing critical medical challenges. (5)

The next day, James Molloy, the Managing Director of Equity Research specializing in Biotechnology & Specialty Pharmaceuticals at Alliance Global Partners, significantly increased his target for XORTX Therapeutics Inc. (Nasdaq: XRTX). (2)

His revised target now stands at $14.00, marking a remarkable shift from the previous target of $9.00. (2)

This adjustment implies an astounding upside potential of more than 600% when compared to XORTX Therapeutics Inc. (Nasdaq: XRTX)’s 52-week low, which was set at $1.98 on 12/ 27/ 2023, as reported by Barchart.com. (6)

Keep reading to see why XORTX Therapeutics Inc. (Nasdaq: XRTX) needs to be added to the top of your watchlist now!

7 Reasons Why XORTX Therapeutics Inc. (Nasdaq: XRTX) coud witness significant upside potential in 2024…

1. Analyst Coverage:

Respected Equity Research Analyst, James Molloy, raised his target for XORTX Therapeutics Inc. (Nasdaq: XRTX) from $9 to $14. His endorsement suggests a potential upside of over 607% from the 52-week low and over 522% from the opening price on 2/5/2024 according to Barchart.com, highlighting significant growth prospects. (2)(6)

2. Extremely Low Float:

According to FinViz.com, (10) XORTX Therapeutics Inc. (Nasdaq: XRTX) boasts an extremely low float of less than 2M shares, increasing the potential for significant price swings due to limited supply. (12)

3. Higher Potential for Growth:

Classified as a nano-cap company, XORTX Therapeutics Inc. (Nasdaq: XRTX) has a market capitalization below $5M as of 2/5/2025 according to Finviz. (10) The smaller size of nano-caps offer a higher potential for rapid valuation changes, adding to its appeal. (13)

4. Innovative Patent:

Recently, XORTX Therapeutics Inc. (Nasdaq: XRTX) made a groundbreaking patent submission for the treatment of Chronic Kidney Disease (CKD). This innovative patent introduces novel formulations and methods designed to enhance the safe and effective utilization of xanthine oxidase inhibitors (XOI) in CKD, presenting promising solutions for various CKD conditions. (5)

5. Untapped Market:

Addressing severe progressive kidney diseases is a primary focus for XORTX Therapeutics Inc. (Nasdaq: XRTX), with a particular emphasis on conditions like Autosomal Dominant Polycystic Kidney Disease (ADPKD), Diabetes Type-2 Nephropathy (T2DN), and Acute Kidney Injury (AKI). These medical conditions present significant unmet needs, underscoring the importance of XORTX's innovative approaches. (1)

6. Blockbuster Pipeline:

The primary focus on ADPKD by XORTX Therapeutics Inc. (Nasdaq: XRTX) highlights a substantial revenue potential of $1.0-1.8 billion USD per year in the US alone. As the exclusivity of the current treatment option is set to expire, the introduction of XRx-008 has the potential to revolutionize ADPKD treatment. (1)

7. Experienced Leadership:

An experienced leadership team, with a track record of success in the pharmaceutical industry, guides XORTX Therapeutics Inc. (Nasdaq: XRTX). The company's strong financial position, amounting to $5.2 million USD, offers stability for the pursuit of research and development goals. (16)(1)

Keep reading to see why XORTX Therapeutics Inc. (Nasdaq: XRTX) needs to be at the top of your watchlist..

Alliance Global Partners Analyst Raises Target for XORTX Therapeutics Inc. (Nasdaq: XRTX)(2)

Chart Source (8)

James Molloy, a seasoned expert in the field of Equity Research, specializing in Biotechnology and Specialty Pharmaceuticals, has recently made headlines by raising his target for XORTX Therapeutics Inc. (Nasdaq: XRTX) from $9 to $14, as reported by Benzinga.com. (2) 

This remarkable adjustment suggests a potential upside of over 607% from XRTX’s 52-week low of $1.98 and a potential 522% from its opening price of $2.25 on 2/5/2025, according to Barchart.com. (6)

Mr. Molloy currently holds the esteemed position of Managing Director at A.G.P./Alliance Global Partners, where he serves as an Equity Research Analyst. (7)

His expertise encompasses an array of therapeutic categories within the biotechnology and pharmaceutical sector, with a primary focus on immuno-oncology, central nervous system disorders, cardiovascular diseases, and anti-infective disorders. (7)

What sets Mr. Molloy apart is his extensive and diverse career within the industry.

Before joining A.G.P., he held the role of Managing Director and Equity Research Analyst specializing in Biotechnology and Specialty Pharmaceuticals at prominent firms, including Laidlaw Capital Markets, Janney Montgomery Scott, and ThinkEquity Partners. Furthermore, his impressive journey includes a position as Vice President of Equity Research at Oppenheimer and Company, where he continued to sharpen his analytical skills. (7)

In light of his extensive experience, James Molloy’s decision to raise the target for XORTX Therapeutics Inc. (Nasdaq: XRTX) carries significant weight.

As XORTX Therapeutics Inc. (Nasdaq: XRTX) continues its journey in the pharmaceutical landscape, James Molloy’s endorsement provides a compelling case for the company’s potential growth and success.

As the biotechnology and pharmaceutical sectors evolve, having a trusted analyst like James Molloy to provide insights and forecasts is invaluable. His ability to navigate the complexities of these industries and identify research opportunities is a testament to his dedication and expertise.

Industry stakeholders and others who are following XORTX Therapeutics Inc. (Nasdaq: XRTX) are undoubtedly paying close attention to his bullish outlook, anticipating the potential for growth in the coming months.

XORTX Therapeutics Inc. (Nasdaq: XRTX) Extremely Low Float Needs Your Immediate Attention! (10)

Image Source (11)

Low float stocks refer to the securities that remain after a company’s stock has been issued to its controlling investors — meaning there are relatively few shares for the public to buy. (12) 

Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions. (12)

Companies with a low float frequently have a large portion of their equity held by controlling investors such as directors and employees, which leaves only a tiny percentage of the stock available for public trading. (12)

That limited supply can cause dramatic price swings if demand changes quickly. (12)

Because low-float stocks have fewer shares available, market participants may have difficulty finding shares available. (12)

XORTX Therapeutics Inc. (Nasdaq: XRTX) has less than 2M shares available in its float (as of 2/6/2024) according to Finviz.com. (10) A low-float stock can make significant moves due to volatility from so few shares being available (7), so this could be one interesting situation to watch closely.

XORTX Therapeutics Inc. (Nasdaq: XRTX) is also considered a nano-cap. In general, nano-cap companies have market capitalizations of less than $50 million. (13) Because nano-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (14)

As of 2/6/2024, XORTX Therapeutics Inc. (Nasdaq: XRTX) has a market cap of less than $5M according to FinViz.com. (10)

Overall, XORTX Therapeutics Inc. (Nasdaq: XRTX) has several positive catalysts, such as its potential for growth and low public float, making it an attractive option for those looking to take advantage of swings with significant potential.

Which is why things could get very interesting and also why you need to start your research on XORTX Therapeutics Inc. (Nasdaq: XRTX) .

XORTX Therapeutics Inc. (Nasdaq: XRTX) Submits Groundbreaking Patent for Chronic Kidney Disease Treatment (5)

Image Source (15)

In a recent development, XORTX Therapeutics Inc. (Nasdaq: XRTX) has unveiled its latest breakthrough – the submission of a groundbreaking patent for the treatment of chronic kidney disease (CKD). (5) 

This novel patent, titled “Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease,” represents a significant stride in the field of kidney disease treatment. Its primary aim is to safeguard novel discoveries and innovative strategies for managing CKD in individuals with varying degrees of kidney function. (5)

XORTX Therapeutics Inc. (Nasdaq: XRTX)’s patent is particularly promising as it introduces new formulations and methods that promise enhanced safety and efficacy in the utilization of xanthine oxidase inhibitors (XOI) for CKD treatment. (5)

The patent’s scope extends to encompass a variety of CKD conditions, including autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy (DN), IgA nephropathy, lupus nephritis, and focal segmental glomerulosclerosis. (5)

The foundation for this pioneering patent was laid with the topline results from the XRX-OXY-101 bridging pharmacokinetic clinical study, which were reported in the first quarter of 2023. This study meticulously evaluated the pharmacokinetics of XORLO™, the company’s proprietary formulation of oral oxypurinol. (5)

Remarkably, the findings from the study underscored the safety and tolerability of XORLO™, as it exhibited no adverse effects across a spectrum of dosing regimens in the 88 subjects who received the dr-ug. (5)

Notably, the results were overwhelmingly positive, highlighting several crucial points: (5)

Enhanced Bioavailability: XORLO™ demonstrated a substantial increase in the bioavailability of oxypurinol, a pivotal factor in its efficacy. (5)

Dose Proportionality: Compared to non-formulated oxypurinol, XORLO™ exhibited significantly increased dose proportionality, which is vital for precision in dosing. (5)

Effective Multiple Dosing: The formulation allowed for a multiple dosing regimen that successfully achieved therapeutic target values. This is a pivotal development for individuals with CKD. (5)

In essence, XORLO™ facilitated substantially improved early oral absorption, resulting in increased circulating concentrations of oxypurinol. This higher concentration is essential for inhibiting uric acid production within the desired therapeutic range, ultimately slowing the progression of CKD. (5)

Dr. Allen Davidoff, CEO of XORTX Therapeutics Inc. (Nasdaq: XRTX), offered insights into this groundbreaking advancement, stating, “The Bridging Pharmacokinetic Study reported this year provided a wealth of clinical data regarding the potential substantive benefit of the novel formulations of the xanthine inhibitor class of dr-ugs. (5) 

Analysis of this data set, the use of in silico based pharmacokinetic modeling of data from the XRX-OXY-101 clinical trial, and further innovation, resulted in a deeper understanding of how to address the challenges of dosing in progressing kidney disease. (5)

This patent application is intended to claim new opportunities to enhance how the xanthine oxidase inhibitor class of dr-ugs may be dosed in the future. Importantly, how to further improve the safe and effective administration of this class of dr-ugs, including oxypurinol.” (5)

XORTX Therapeutics Inc. (Nasdaq: XRTX)’s patent submission marks a significant leap forward in the realm of CKD treatment, offering new hope for individuals facing this debilitating condition. (5) 

With the promise of enhanced safety and efficacy, this groundbreaking patent paves the way for more effective CKD management in the future. (5)

SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & NEWS.

Getting the Right News Before Everyone Else Does, is FREE…

Terms | Privacy Policy Message and data rates may apply. Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.​

XORTX Therapeutics Inc. (Nasdaq: XRTX) on the Verge of Revolutionizing Kidney Disease Treatment (1)

XORTX Therapeutics Inc. (Nasdaq: XRTX) is emerging as a frontrunner in the field of biopharmaceuticals, with its innovative dr-ug-based therapies targeting serious progressive kidney diseases. The company has recently garnered attention from Wall Street analysts, leading to an increase in their target. (1) 

Let’s dive into the key factors that make XORTX Therapeutics Inc. a compelling player in the pharmaceutical industry.

Addressing Critical Unmet Medical Needs (1)

XORTX Therapeutics is on a mission to develop dr-ug-based therapies for severe progressive kidney diseases characterized by high unmet medical needs. These conditions include Autosomal Dominant Polycystic Kidney Disease (ADPKD), Diabetes Type-2 Nephropathy (T2DN), and Acute Kidney Injury (AKI). These diseases have long been a challenge for both patients and healthcare providers due to the lack of effective treatment options.(1)

Innovative Pipeline with Strong Patent Protection (1)

Image Source (1)

XORTX’s proprietary pipeline-in-a-product technology has yielded three patent families with extensive therapeutic claims. Their flagship dr-ug, Oxypurinol, has been the subject of numerous third-party studies, involving over 700 treated patients, including multiple Phase 2 studies. This research has provided deep insights into Oxypurinol’s mechanism of action (MoA) and its potential as a groundbreaking treatment. (1)

Furthermore, XORTX Therapeutics enjoys robust patent protection until 2034, ensuring that their innovative therapies remain exclusive in the market for years to come. (1) 

Focused on ADPKD with High Revenue Potential (1)

Image Source (1)

XORTX’s primary focus is on the XRx-008 program for ADPKD, which presents a significant revenue potential of $1.0-1.8 billion USD per year in the US alone. ADPKD represents a strong unmet medical need, with only one currently approved dr-ug subject to a black box warning and its market exclusivity set to expire in 2025. XRx-008, with its Orphan dr-ug Designation from the FDA and a confirmed path to accelerated approval, could potentially replace existing treatments and generate substantial revenue for XORTX Therapeutics.(1) 

Short-Term Catalysts for Growth (1)

Industry stakeholders and followers of XORTX Therapeutics Inc. (Nasdaq: XRTX) have reasons to be optimistic as the company anticipates signing a global licensing deal in 2023/2024. (1)

Such an agreement could provide non-dilutive funding, bolstering XORTX Therapeutics Inc. (Nasdaq: XRTX)’s financial position as it prepares to initiate a Phase 3 pivotal registration clinical trial with approximately 200 patients, a crucial milestone in bringing innovative kidney disease treatments to market. (1)

Strong Financial Position and Experienced Leadership (1)

XORTX Therapeutics Inc. boasts a robust cash position of $5.2 million USD, a noteworthy achievement considering its market capitalization of $6 million USD. This financial stability provides the company with a runway for approximately 14 months, allowing them to pursue their research and development objectives. (1)

The company’s senior team, led by CEO Allen W. Davidoff, Ph.D., has a track record of success in the pharmaceutical industry, having played key roles in the development of Oxypurinol in prior ventures. (1)

Notably, Cynapsus Therapeutics was acquired for $624 million USD, and Trillium Therapeutics was bought for $2.2 billion USD by Pfizer, showcasing the leadership’s ability to create significant shareholder value. (1)

Meet the Senior Management Team (16)

Dr. Allen W. Davidoff, PhD (16)
Chief Executive Officer

With over 15 years of experience in dr-ug development, Dr. Allen Davidoff is the visionary founder and CEO of XORTX Therapeutics Inc. His impressive track record includes significant clinical and regulatory expertise, overseeing two investigational new dr-ug (“IND”) applications or supplemental IND’s, managing two phase I studies (four of which were multi-country), seven phase II studies, and contributing to one New dr-ug Application (NDA). Before establishing XORTX, Dr. Davidoff served as the Chief Scientific Officer, VP Product Development, and co-founder of Stem Cell Therapeutics Corp. for seven years, listed on NASDAQ under Trillium TRIL. Additionally, he held the position of Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp. (16)

James Fairbairn (16)
Interim Chief Financial Officer

James Fairbairn brings an impressive financial acumen to XORTX Therapeutics Inc. Having served as the Company’s Chief Financial Officer from November 2018 through July 2021, he boasts over 20 years of experience with publicly-traded companies. A Chartered Professional Accountant, Mr. Fairbairn obtained his CPA designation in 1987 and is also certified by the Institute as a Director. He holds a B.A. from the University of Western Ontario. (16)

Dr. Stephen Haworth (16)
Chief Medical Officer

Dr. Stephen Haworth, with a wealth of over 25 years of experience in global dr-ug development and senior leadership, serves as XORTX's Chief Medical Officer. His extensive background spans both start-up ventures and Fortune 500 pharmaceutical companies, across the United States and Europe. Dr. Haworth possesses broad clinical and regulatory experience, from infectious diseases to nephrology and cardiovascular diseases. More recently, he has been instrumental in programs targeting the treatment and prevention of SARS-CoV infection. Dr. Haworth earned his medical degree from University College Hospital Medical School, University of London, graduating with Honors. (16)

Dr. David MacDonald (16)
Chief Technology Officer

Dr. David MacDonald, a seasoned professional with over 30 years of accomplishments in dr-ug development and leadership within the pharma and biotech industries, holds the position of Chief Technology Officer at XORTX Therapeutics Inc. Prior to joining XORTX, Dr. MacDonald was the CTO and later President of MSI Methylation Sciences Inc., a clinical-stage pharmaceutical company, where he led R&D, pharmaceutical product development, and clinical development. His career also includes the role of President and CEO of Active Pass Pharmaceutics and leadership positions in various small and large pharma biotech companies. Dr. MacDonald is a prolific inventor, with over 20 patents issued globally, and has published 14 manuscripts in peer-reviewed journals. He earned his Ph.D. in Chemistry from the University of Alberta, with a focus on enzymology. (16)

Dr. Stacy Evans (16)
Chief Business Officer

Dr. Stacy Evans, a seasoned executive consultant with nearly 25 years of experience in commercial development and business development, serves as the Chief Business Officer of XORTX Therapeutics Inc. His remarkable career includes a 12-year tenure at Pfizer, where he spearheaded multiple transactions, including significant contributions to the rare disease space. For the past seven years, Dr. Evans has provided high-level consultancy to small to mid-size private and public biopharmaceutical companies, often acting as Chief Business Officer. Dr. Evans holds an M.D. from McGill University and an Executive MBA from Columbia University. (16)

Little-Known Pharma Eyes $1 Billion Blockbuster as Wall Street Analyst Raises Target – Suggesting Significant Upside Potential… (1)(2)

See why now could be the best time to start your research on XORTX Therapeutics Inc. (Nasdaq: XRTX)

7 Reasons Why XORTX Therapeutics Inc. (Nasdaq: XRTX) coud witness significant upside potential in 2024…

1. Analyst Coverage:

Respected Equity Research Analyst, James Molloy, raised his target for XORTX Therapeutics Inc. (Nasdaq: XRTX) from $9 to $14. His endorsement suggests a potential upside of over 607% from the 52-week low and over 522% from the opening price on 2/5/2024 according to Barchart.com, highlighting significant growth prospects. (2)(6)

2. Extremely Low Float:

According to FinViz.com, (10) XORTX Therapeutics Inc. (Nasdaq: XRTX) boasts an extremely low float of less than 2M shares, increasing the potential for significant price swings due to limited supply. (12)

3. Higher Potential for Growth:

Classified as a nano-cap company, XORTX Therapeutics Inc. (Nasdaq: XRTX) has a market capitalization below $5M as of 2/5/2025 according to Finviz. (10) The smaller size of nano-caps offer a higher potential for rapid valuation changes, adding to its appeal. (13)

4. Innovative Patent:

Recently, XORTX Therapeutics Inc. (Nasdaq: XRTX) made a groundbreaking patent submission for the treatment of Chronic Kidney Disease (CKD). This innovative patent introduces novel formulations and methods designed to enhance the safe and effective utilization of xanthine oxidase inhibitors (XOI) in CKD, presenting promising solutions for various CKD conditions. (5)

5. Untapped Market:

Addressing severe progressive kidney diseases is a primary focus for XORTX Therapeutics Inc. (Nasdaq: XRTX), with a particular emphasis on conditions like Autosomal Dominant Polycystic Kidney Disease (ADPKD), Diabetes Type-2 Nephropathy (T2DN), and Acute Kidney Injury (AKI). These medical conditions present significant unmet needs, underscoring the importance of XORTX's innovative approaches. (1)

6. Blockbuster Pipeline:

The primary focus on ADPKD by XORTX Therapeutics Inc. (Nasdaq: XRTX) highlights a substantial revenue potential of $1.0-1.8 billion USD per year in the US alone. As the exclusivity of the current treatment option is set to expire, the introduction of XRx-008 has the potential to revolutionize ADPKD treatment. (1)

7. Experienced Leadership:

An experienced leadership team, with a track record of success in the pharmaceutical industry, guides XORTX Therapeutics Inc. (Nasdaq: XRTX). The company's strong financial position, amounting to $5.2 million USD, offers stability for the pursuit of research and development goals. (16)(1)

Source 1: https://d1io3yog0oux5.cloudfront.net/_67cb83c3d10e4bc06f26dc86a05ee43b/xortx/db/856/7652/pdf/XORTX+Corporate+Presentation_Jan_2024.pdf
Source 2: https://www.benzinga.com/quote/XRTX
Source 3: https://www.investopedia.com/terms/b/blockbuster-dr-ug.asp#:~:text=A%20blockbuster%20drug%20is%20a,cancer%2C%20that%20many%20individuals%20face.
Source 4: https://m.foolcdn.com/media/dubs/original_images/pills_on_money_GettyImages-507799948.jpg
Source 5: https://finance.yahoo.com/news/xortx-submits-patent-treatment-chronic-120000319.html
Source 6: https://www.barchart.com/stocks/quotes/XRTX/price-history/historical?orderBy=tradeTime&orderDir=desc
Source 7: https://www.allianceg.com/researchteammember/james-molloy/
Source 8: https://www.otcmarkets.com/stock/XRTX/overview
Source 10: https://finviz.com/quote.ashx?t=XRTX&p=d
Source 11: https://investmentu.com/low-float-stocks/
Source 12: https://www.sofi.com/learn/content/understanding-low-float-stocks/
Source 13: https://www.investopedia.com/terms/n/nanocap.asp
Source 14: https://www.benzinga.com/money/best-nano-cap-stocks
Source 15: https://www.kidneyfund.org/sites/default/files/styles/hero_bg/public/media/images/Kidneys/kidney-magnified-body.jpg?itok=m1EoamTn
Source 16: https://www.xortx.com/about/management-team

GET RED-HOT NEWS DELIVERED RIGHT TO YOUR INBOX:

Getting the Right News Before Everyone Else Does, is FREE…

Terms | Privacy Policy Message and data rates may apply. Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.​